StockUS listing USKODNASDAQHealthcareCapital Destroyer

Kodiak Sciences Inc(KOD) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk56Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 6.35Bn
Reward Ratingⓘ34 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ56 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on KOD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kodiak Sciences Inc?

, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

AI Brief Pro

The brief on Kodiak Sciences Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Kodiak Sciences Inc?

, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 6.35B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.979
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
830,000 shares
$2.7M
12333,556 shares
$31.4M
3-6months
0
0
6-9months
0
0
9-12months
0
0